Mussivand T
The Cardiovascular Devices Division, University of Ottawa Heart Institute, Ontario, Canada.
J Card Surg. 1999 May-Jun;14(3):218-28. doi: 10.1111/j.1540-8191.1999.tb00983.x.
During the last four decades substantial efforts have been made in the development of effective mechanical circulatory devices. Since the first clinical utilization in the 1960s, the field has gone from the stage of clinical experimentation to that of a valid and effective heart failure treatment alternative. Experience gained during the short-term use of these devices, typically as a bridge to cardiac transplantation, has led to increased expectations of devices capable of long-term or permanent support to be used as a permanent treatment for end-stage heart failure patients. This article reviews the history, current state of the art, and future of the field of mechanical circulatory devices.
Mechanical circulatory devices can be classified into three major categories: (1) total artificial hearts, (2) pulsatile ventricular assist devices, and (3) nonpulsatile ventricular assist devices. The most widely used devices have been the pulsatile ventricular assist devices with more than 5,800 reported cases, whereas the use of total artificial hearts has been limited to less than 350 reported cases. Nonpulsatile devices have been used clinically, but only in short-term cases (i.e., hours and days), whereas the pulsatile devices have been used in the long-term application, with patients supported for weeks, months, and in a small number of cases, years. The technological evolution of these devices has gone from large, extracorporeal systems designed to keep the patient alive in the intensive care unit (ICU) until a donor organ could be found, to portable devices that allow the patient to be mobilized outside of the hospital setting.
The clinical experience with mechanical circulatory devices as a bridge to cardiac transplantation has saved the lives of thousands of patients. Exciting new research discoveries related to recovery of native heart function during extended circulatory support have provided new hope for many more patients. Additional research efforts currently underway are being tested at various laboratories around the world and will soon provide the next generation of systems. These new systems will offer the recipients an unparalleled quality of life with minimal limitations on daily activities. The progress in this field has reached the point where circulatory support will soon be considered a valid long-term or permanent therapy and an elective to transplantation.
在过去的四十年里,人们在开发有效的机械循环装置方面付出了巨大努力。自20世纪60年代首次临床应用以来,该领域已从临床实验阶段发展到成为一种有效且可行的心力衰竭治疗选择阶段。这些装置短期使用(通常作为心脏移植的桥梁)所积累的经验,使得人们对能够长期或永久支持的装置的期望增加,这些装置将被用作终末期心力衰竭患者的永久性治疗方法。本文回顾了机械循环装置领域的历史、当前技术水平和未来发展。
机械循环装置可分为三大类:(1)全人工心脏,(2)搏动性心室辅助装置,(3)非搏动性心室辅助装置。使用最广泛的装置是搏动性心室辅助装置,报告病例超过5800例,而全人工心脏的使用报告病例数不到350例。非搏动性装置已用于临床,但仅用于短期情况(即数小时和数天),而搏动性装置已用于长期应用,患者得到数周、数月的支持,少数情况下长达数年。这些装置的技术发展已从大型体外系统(旨在使患者在重症监护病房(ICU)中维持生命直至找到供体器官)发展到便携式装置,使患者能够在医院环境之外活动。
作为心脏移植桥梁的机械循环装置的临床经验挽救了数千名患者的生命。与延长循环支持期间心脏功能恢复相关的令人兴奋的新研究发现为更多患者带来了新希望。目前正在进行的其他研究工作正在世界各地的各个实验室进行测试,并将很快提供下一代系统。这些新系统将为接受者提供无与伦比的生活质量,对日常活动的限制最小。该领域的进展已达到这样一个程度,即循环支持很快将被视为一种有效的长期或永久治疗方法以及移植的一种选择。